Literature DB >> 22180642

Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts.

Mark O Goodarzi1, Michelle R Jones, Xiaohui Li, Angela K Chua, Obed A Garcia, Yii-Der I Chen, Ronald M Krauss, Jerome I Rotter, Wendy Ankener, Richard S Legro, Ricardo Azziz, Jerome F Strauss, Andrea Dunaif, Margrit Urbanek.   

Abstract

BACKGROUND: Polycystic ovary syndrome (PCOS) is a complex endocrine disorder with a strong familial component. PCOS is characterised by hyperandrogenaemia and irregular menses. A recent genome-wide association study (GWAS) of PCOS in a Chinese cohort identified three reproducible PCOS susceptibility loci mapping to 2p16.3 (luteinising hormone/choriogonadotropin receptor; LHCGR), 2p21 (thyroid associated protein; THADA), and 9q33.3 (DENN/MADD domain containing 1A; DENNDIA). The impact of these loci in non-Chinese PCOS cohorts remains to be determined. METHODS AND
RESULTS: The study tested association with PCOS of seven single nucleotide polymorphisms mapping to the three Chinese PCOS loci in two European derived PCOS cohorts (cohort A = 939 cases and 957 controls; cohort B = 535 cases and 845 controls). Cases fulfilled the National Institute of Child Health & Human Development criteria for PCOS. Variation in DENND1A was strongly associated with PCOS in the study cohort (p(combined cohorts)=10(-8)); multiple variants in THADA were also associated with PCOS, while there was no significant evidence for association of LHCGR variation with PCOS. The present study had >80% power to detect an effect of similar size as was observed by Chen et al for DENND1A and THADA, but reduced power (at <40%) for LHCGR at p=0.0001. The study had sufficient power (57-88%) for LHCGR at p=0.01.
CONCLUSIONS: At least two of the PCOS susceptibility loci identified in the Chinese PCOS GWAS (DENND1A and THADA) are also associated with PCOS in European derived populations, and are therefore likely to be important in the aetiology of PCOS regardless of ethnicity. The analysis of the LHCGR gene was not sufficiently powered to detect modest effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22180642      PMCID: PMC3536488          DOI: 10.1136/jmedgenet-2011-100427

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  34 in total

1.  Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits.

Authors:  S Purcell; S S Cherny; P C Sham
Journal:  Bioinformatics       Date:  2003-01       Impact factor: 6.937

2.  Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.

Authors:  Ricardo Azziz; Enrico Carmina; Didier Dewailly; Evanthia Diamanti-Kandarakis; Hector F Escobar-Morreale; Walter Futterweit; Onno E Janssen; Richard S Legro; Robert J Norman; Ann E Taylor; Selma F Witchel
Journal:  J Clin Endocrinol Metab       Date:  2006-08-29       Impact factor: 5.958

3.  Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity.

Authors:  Richard S Legro; Rhonda Bentley-Lewis; Deborah Driscoll; Steve C Wang; Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

4.  Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin.

Authors:  M Urbanek; R S Legro; D A Driscoll; R Azziz; D A Ehrmann; R J Norman; J F Strauss; R S Spielman; A Dunaif
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

5.  Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome.

Authors:  Susan Sam; Richard S Legro; Rhonda Bentley-Lewis; Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2005-05-17       Impact factor: 5.958

6.  Fine mapping of genetic susceptibility to polycystic ovary syndrome on chromosome 19p13.2 and tests for regulatory activity.

Authors:  D R Stewart; B A Dombroski; M Urbanek; W Ankener; K G Ewens; J R Wood; R S Legro; J F Strauss; A Dunaif; R S Spielman
Journal:  J Clin Endocrinol Metab       Date:  2006-07-25       Impact factor: 5.958

Review 7.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

Authors: 
Journal:  Hum Reprod       Date:  2004-01       Impact factor: 6.918

Review 8.  Polycystic ovary syndrome: syndrome XX?

Authors:  Susan Sam; Andrea Dunaif
Journal:  Trends Endocrinol Metab       Date:  2003-10       Impact factor: 12.015

9.  Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.

Authors:  R S Legro; D Driscoll; J F Strauss; J Fox; A Dunaif
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

10.  The prevalence and features of the polycystic ovary syndrome in an unselected population.

Authors:  Ricardo Azziz; Keslie S Woods; Rosario Reyna; Timothy J Key; Eric S Knochenhauer; Bulent O Yildiz
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

View more
  69 in total

Review 1.  Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome.

Authors:  Selma F Witchel; Sergio E Recabarren; Frank González; Evanthia Diamanti-Kandarakis; Kai I Cheang; Antoni J Duleba; Richard S Legro; Roy Homburg; Renato Pasquali; Rogerio A Lobo; Christos C Zouboulis; Fahrettin Kelestimur; Franca Fruzzetti; Walter Futterweit; Robert J Norman; David H Abbott
Journal:  Endocrine       Date:  2012-06-04       Impact factor: 3.633

2.  Persistence pays off for PCOS gene prospectors.

Authors:  Jerome F Strauss; Jan M McAllister; Margrit Urbanek
Journal:  J Clin Endocrinol Metab       Date:  2012-07       Impact factor: 5.958

3.  Han Chinese polycystic ovary syndrome risk variants in women of European ancestry: relationship to FSH levels and glucose tolerance.

Authors:  R Saxena; N A Georgopoulos; T J Braaten; A C Bjonnes; V Koika; D Panidis; C K Welt
Journal:  Hum Reprod       Date:  2015-04-22       Impact factor: 6.918

4.  Perspectives in Polycystic Ovary Syndrome: From Hair to Eternity.

Authors:  Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2016-02-23       Impact factor: 5.958

Review 5.  Nonalcoholic fatty liver disease and polycystic ovary syndrome.

Authors:  Evangeline Vassilatou
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

6.  The role of DENND1A and CYP19A1 gene variants in individual susceptibility to obesity in Turkish population-a preliminary study.

Authors:  Ela Kadioglu; Beril Altun; Çağrı İpek; Esra Döğer; Aysun Bideci; Hadi Attaran; İsmet Çok
Journal:  Mol Biol Rep       Date:  2018-09-19       Impact factor: 2.316

Review 7.  Ontogeny of polycystic ovary syndrome and insulin resistance in utero and early childhood.

Authors:  David H Abbott; Fida Bacha
Journal:  Fertil Steril       Date:  2013-07       Impact factor: 7.329

Review 8.  Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  J Mol Endocrinol       Date:  2018-10-16       Impact factor: 5.098

Review 9.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

Review 10.  Genetics of the polycystic ovary syndrome.

Authors:  Gülüm Kosova; Margrit Urbanek
Journal:  Mol Cell Endocrinol       Date:  2012-10-16       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.